

Nazia Chaudhuri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8772681/nazia-chaudhuri-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

1,316
citations

19
h-index

35
g-index

99
ext. papers

1,924
ext. citations

7
avg, IF

4.71
L-index

#	Paper	IF	Citations
61	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. <i>ERJ Open Research</i> , 2021 , 7,	3.5	5
60	The burden of progressive fibrotic interstitial lung disease across the UK. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	5
59	Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service. <i>Advances in Therapy</i> , 2021 , 38, 4505-4519	4.1	3
58	Substrate for the Myocardial Inflammation-Heart Failure Hypothesis Identified Using Novel USPIO Methodology. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 365-376	8.4	13
57	Myocardial involvement in eosinophilic granulomatosis with polyangiitis evaluated with cardiopulmonary magnetic resonance. <i>International Journal of Cardiovascular Imaging</i> , 2021 , 37, 1371-1381	3.5	5
56	Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. <i>Advances in Therapy</i> , 2021 , 38, 268-277	4.1	2
55	Reply to Althwaybi : Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 522-524	10.2	
54	Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation. <i>EClinicalMedicine</i> , 2021 , 40, 101122	11.3	5
53	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	6
52	Treatment of fibrotic interstitial lung disease: current approaches and future directions. <i>Lancet, The</i> , 2021 , 398, 1450-1460	40	7
51	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. <i>Frontiers in Medicine</i> , 2021 , 8, 699644	4.9	3
50	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	2
49	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 1001-1008	3.8	1
48	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 453-460	35.1	154
47	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	18
46	Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 218-224	1.1	2
45	Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 231-233	1.1	1

44	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1656-1665	10.2	72
43	Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. <i>International Journal of Audiology</i> , 2020 , 59, 889-890	2.6	38
42	How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians. <i>ERJ Open Research</i> , 2020 , 6,	3.5	4
41	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 771-779	35.1	34
40	Association of Cardiovascular Disease With Respiratory Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2166-2177	15.1	60
39	Sarcoidosis in the UK: insights from British Thoracic Society registry data. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000357	5.6	13
38	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. <i>Advances in Therapy</i> , 2019 , 36, 2193-2204	4.1	4
37	The therapy of idiopathic pulmonary fibrosis: what is next?. <i>European Respiratory Review</i> , 2019 , 28,	9.8	68
36	Pulmonary involvement in antiphospholipid syndrome 2019 , 124-139		
35	No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	12
34	Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. <i>Respiratory Research</i> , 2019 , 20, 7	7.3	13
33	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. <i>Respiration</i> , 2019 , 97, 173-184	3.7	27
32	Physiological predictors of Hypoxic Challenge Testing (HCT) outcomes in Interstitial Lung Disease (ILD). <i>Respiratory Medicine</i> , 2018 , 135, 51-56	4.6	4
31	Idiopathic pulmonary fibrosis: a clinical update. <i>British Journal of General Practice</i> , 2018 , 68, 249-250	1.6	
30	Idiopathic Pulmonary Fibrosis (IPF): An Overview. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	111
29	A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey 2018 ,		4
28	Drug induced interstitial lung disease: a systematic review 2018 ,		5
27	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018 , 12, 1753466618800618	4.9	27

26	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	117
25	Feather bedding as a cause of hypersensitivity pneumonitis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017 , 110, 233-234	2.7	3
24	Bagpipe lung; a new type of interstitial lung disease?. <i>Thorax</i> , 2017 , 72, 380-382	7.3	14
23	Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. <i>Clinical and Translational Medicine</i> , 2017 , 6, 41	5.7	23
22	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. <i>Journal of Thoracic Disease</i> , 2017 , 9, 4700-4707	2.6	17
21	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. <i>Drugs and Aging</i> , 2017 , 34, 647-653	4.53	9
20	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. <i>Clinical Medicine Insights Therapeutics</i> , 2017 , 9, 1179559X1771912	0	2
19	Nintedanib for treating idiopathic pulmonary fibrosis. <i>British Journal of Health Care Management</i> , 2016 , 22, 250-251	0.4	
18	Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	102
17	A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	26
16	IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. <i>Advances in Therapy</i> , 2015 , 32, 87-107	4.1	28
15	P6 Early Clinical Experience With Nintedanib In two centre review. <i>Thorax</i> , 2015 , 70, A77.2-A77	7.3	
14	P28 Real World MDT Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Thorax</i> , 2015 , 70, A90.1-A90	7.3	3
13	S91 A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis. <i>Thorax</i> , 2015 , 70, A52.1-A52	7.3	4
12	P34 Sarcoidosis and co-existent Aspergillus lung disease. <i>Thorax</i> , 2015 , 70, A92.3-A93	7.3	
11	Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , 2014 , 108, 224-6	4.6	52
10	P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim Results. <i>Thorax</i> , 2014 , 69, A196-A196	7.3	
9	M263 A Quarter Of IpF Patients Not Eligible For Pirfenidone Treatment Due To The Nice Criteria Significantly Decline Over Time. <i>Thorax</i> , 2014 , 69, A218-A218	7.3	

8	M264 Health And Economic Impact Of Prescribing Pirfenidone. <i>Thorax</i> , 2014 , 69, A218-A219	7.3	
7	S13 Sole use of forced vital capacity as per national institute of health and care excellence criteria disadvantage 2 in 5 people with idiopathic pulmonary fibrosis. <i>Thorax</i> , 2013 , 68, A10.1-A10	7.3	
6	Summary of the British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. <i>Thorax</i> , 2013 , 68, 786-7	7.3	37
5	Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. <i>PLoS ONE</i> , 2012 , 7, e51107	3.7	18
4	Basic science of the innate immune system and the lung. <i>Paediatric Respiratory Reviews</i> , 2008 , 9, 236-42	4.8	22
3	Reducing the toll of inflammatory lung disease. <i>Chest</i> , 2007 , 131, 1550-6	5.3	39
2	Toll-like receptors and chronic lung disease. <i>Clinical Science</i> , 2005 , 109, 125-33	6.5	59
1	Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.		3